Prosecution Insights
Last updated: November 20, 2026

Luisalberto Gonzalez, USPTO Patent Examiner

Listed by the USPTO as GONZALEZ, LUISALBERTO

Tech Center 1600 • Art Units: 1624 1626 1632

This examiner grants 58% of resolved cases

Analysis

GONZALEZ, LUISALBERTO is assigned to tech center 1600 and art unit 1624. The profile includes 168 resolved cases, with an allowance rate of 58.3% and a median of 1077 days to allowance. The interview lift is 47.6%, making interview activity a substantial part of the recorded outcome pattern.

The leading companies are Orcosa Inc., Syngenta AG, and Yale University. The top firms are PATTERSON + SHERIDAN, L.L.P., BakerHostetler, and Dentons US LLP. Practitioners may give interviews focused attention when developing a prosecution plan, while using the allowance and timing figures to establish broad historical expectations.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

58.3%
Allow Rate
-1.7% vs TC avg
236
Total Applications
+47.6%
Interview Lift
1077
Avg Prosecution Days
Based on 168 resolved cases, 2023–2026

Rejection Statute Breakdown

2.8%
§101 Eligibility
13.2%
§102 Novelty
38.0%
§103 Obviousness
31.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18953295 Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity Non-Final OA Merck Patent GmbH
18575717 USE OF FLUAZIFOP-P-BUTYL FOR INSECT CONTROL Non-Final OA SYNGENTA CROP PROTECTION AG
18552055 SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
19347194 METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION Final Rejection SK CHEMICALS Co., Ltd.
18711747 COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG Non-Final OA Shionogi & Co., Ltd.
18934169 COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES Non-Final OA Beth Israel Deaconess Medical Center, Inc.
18703125 COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN Non-Final OA Duke University
18683106 COMPOSITIONS FOR ORGAN AND TISSUE PRESERVATION Non-Final OA Yale University
18571471 ANTI-CANCER COMPOUNDS AND METHODS OF USE Final Rejection YALE UNIVERSITY
18611505 Substituted Bimane Compounds and Methods of Use Thereof Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17359714 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE Non-Final OA IMBRIA PHARMACEUTICALS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Luisalberto Gonzalez's allowance rate?

58.3% of resolved applications examined by Luisalberto Gonzalez were allowed (168 resolved cases), compared with 54.4% across Art Unit 1624 over the last five years.

Does an interview help with examiner Luisalberto Gonzalez?

This examiner's interview lift is +47.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Luisalberto Gonzalez take to allow a patent?

Applications allowed by Luisalberto Gonzalez took 1,077 days on average from filing to allowance.

Which art unit does examiner Luisalberto Gonzalez work in?

Luisalberto Gonzalez examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month